The dailysciencedigest’s Podcast

Cancer Immunotherapy Biomarkers — CHD1/MAP3K7 Deletion Insights

Listen Later

Cancer immunotherapy biomarkers and CHD1/MAP3K7 deletion in predicting immunotherapy response

New insights into dual-gene deletion, tumor response to immunotherapy, and emerging immunotherapy success predictors
Understand how CHD1 and MAP3K7 co-deletion could guide personalized cancer treatment and precision oncology decisions

What You'll Learn:

  • How CHD1 and MAP3K7 co-deletion functions as a potential cancer immunotherapy biomarker to predict which patients may benefit most from treatment
  • Why CHD1+MAP3K7 co-deletion appears in roughly 8% of primary and 15% of metastatic prostate tumors, and how that prevalence shapes clinical and research priorities
  • What preclinical mouse data reveal about a 5-fold increase in CD8+ T-cell infiltration and a 6-fold rise in STING pathway transcripts in dual-deleted tumors
  • How a Johns Hopkins pembrolizumab cohort (n=57) showed a 33% objective response rate in dual-deleted tumors versus 7% in non-deleted tumors, and why this signal still requires independent validation
  • Practical ways these findings could inform biomarker development, patient stratification, and immunotherapy trial design in prostate cancer and other solid tumors
  • How CHD1/MAP3K7 deletion research integrates with existing biomarkers for cancer treatment, including PD-L1, MSI, and TMB, in predicting immunotherapy response
  • Key methodological and translational challenges that must be addressed before CHD1/MAP3K7 co-deletion can be used as a routine immunotherapy success predictor in the clinic
    • ...more
    View all episodesView all episodes
    Download on the App Store
    The dailysciencedigest’s PodcastBy dailysciencedigest